Výsledky vyhledávání - "Szendrői Miklós"

Akademický článek

Current indications for denosumab in benign bone tumours

Autor: Antal Imre, Sápi Zoltán, Szendrői Miklós

Publikováno v: EFORT Open Reviews, Vol 8, Iss 12, Pp 895-905 (2023)

Denosumab is a fully humanised monoclonal antibody to RANK ligand, inhibiting the RANK–RANKL pathway. It promotes the apoptosis of osteoclast-like giant cells, a secondary ossification and connective tissue formation. Given its high efficacy, denos

Externí odkaz: https://doaj.org/article/1828996cd5ad46c8bb8b2be7eea3d916

Zobrazit plný text záznamu

Akademický článek

Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)

Autor: Changchien Yi-Che, Tátrai Péter, Papp Gergő, Sápi Johanna, Fónyad László, Szendrői Miklós, Pápai Zsuzsanna, Sápi Zoltán

Publikováno v: Journal of Translational Medicine, Vol 10, Iss 1, p 216 (2012)

Abstract Background Enhancer of zeste homologue 2 (EZH2) is a polycomb group (PcG) family protein. Acting as a histone methyltransferase it plays crucial roles in maintaining epigenetic stem cell signature, while its deregulation leads to tumor devel

Externí odkaz: https://doaj.org/article/d9f5137305984ce78bbb4b314b533fba

Zobrazit plný text záznamu

Akademický článek

Correlation between DNA ploidy, metaphase high-resolution comparative genomic hybridization results and clinical outcome of synovial sarcoma

Autor: Papp Gergő, Fónyad László, Pápai Zsuzsanna, Antal Imre, Szendrői Miklós, Szemlaky Zsuzsanna, Balogh Zsófia, Changchien Yi C, Sápi Zoltán

Publikováno v: Diagnostic Pathology, Vol 6, Iss 1, p 107 (2011)

Abstract Background Although synovial sarcoma is the 3rd most commonly occurring mesenchymal tumor in young adults, usually with a highly aggressive clinical course; remarkable differences can be seen regarding the clinical outcome. According to comp

Externí odkaz: https://doaj.org/article/6fb2374004d04f4d964e9803fc760c26

Zobrazit plný text záznamu